NEW YORK (GenomeWeb News) – XDx said this week that health insurer Cigna has issued a positive coverage decision for XDx's AlloMap Molecular Expression Testing for potential heart transplant rejection.

The policy, which took effect immediately, applies to about 13.8 million lives covered by Cigna. Barry Kane, senior director of finance and reimbursement at XDx, said the firm is "particularly pleased" that Cigna is formally covering AlloMap for patients six months to five years post-heart transplant.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.